• S Tag Peptide: Workflow Parameters and Best Practices

  2026-08-04

  S Tag Peptide enables efficient detection and purification of recombinant proteins, especially when solubility is a limiting factor. It is not suitable for protocols requiring ethanol-based solubilization or long-term aqueous storage, and does not provide catalytic activity independently.

• Gepotidacin: Redefining Antibacterial Strategies for Resista

  2026-08-03

  Explore how Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene bacterial DNA gyrase inhibitor, is transforming the landscape of antibacterial research and translational medicine. This thought-leadership article bridges detailed mechanistic insights with strategic protocols and forward-thinking guidance for researchers tackling antibiotic resistance, distinguishing its perspective from conventional product summaries.

• GM 6001 (Galardin): Precision MMP Inhibition for Translation

  2026-08-03

  GM 6001 (Galardin) empowers researchers to modulate matrix metalloproteinase activity with nanomolar precision, enabling robust control of extracellular matrix remodeling in disease models. This article bridges advanced protocol design with troubleshooting strategies, leveraging new mechanistic insights from renal cancer research and integrating cross-disciplinary workflows for maximum impact.

• Phalloidin (B7678): Technical Guidance for F-Actin Stabiliza

  2026-08-02

  Phalloidin (SKU B7678) is used to achieve robust, selective visualization and stabilization of filamentous actin in fixed or permeabilized cells and tissues. It is not appropriate for live-cell imaging or for studies requiring reversible actin dynamics. This article provides actionable guidance for effective workflow design and troubleshooting.

• Puromycin dihydrochloride: Protocol Parameters and QC Guide

  2026-08-01

  Puromycin dihydrochloride is an aminonucleoside antibiotic widely used for rapid protein synthesis inhibition and as a selection marker for pac gene-expressing cell lines. Optimal use depends on careful control of assay concentration, storage, and workflow design to avoid cytotoxicity in non-resistant cells. It should not be used for cell lines lacking puromycin N-acetyltransferase or where long-term solution stability is required.

• Viperin Disrupts Coronavirus Replication via nsp8 Targeting

  2026-07-31

  This study reveals a novel antiviral mechanism in which viperin inhibits coronavirus replication by binding to non-structural protein 8 (nsp8), disrupting the assembly of the replication-transcription complex and impairing RNA-dependent RNA polymerase (RdRp) activity. The work highlights both ddhCTP-dependent and independent pathways, offering new insights for broad-spectrum antiviral strategy development.

• Doxycycline in Tumor Microenvironment Modulation and Precisi

  2026-07-31

  Explore the multifaceted role of Doxycycline, a tetracycline antibiotic, in modulating the tumor microenvironment and enhancing precision cancer research. This in-depth analysis uniquely connects metalloproteinase inhibition, immunomodulation, and targeted delivery, offering actionable insights for advanced assay development.

• Ricin-Induced Necroptosis in Lung Epithelium: Mechanistic In

  2026-07-30

  Kempen et al. (2023) reveal that ricin toxin triggers necroptosis in lung epithelial cells via a bystander inflammatory effect, implicating cytokines and HMGB1 in propagating cell death. This work advances the mechanistic understanding of lung injury due to toxins and highlights new considerations for apoptosis and inflammasome activation research.

• Metabolite Regulation of TET2: Protocol Advances and Implica

  2026-07-30

  This article reviews a robust experimental protocol for elucidating how small-molecule metabolites regulate the activity of TET2, a key epigenetic enzyme. By integrating biochemical assays with STD NMR spectroscopy, the study establishes a framework for identifying both activators and inhibitors of TET2, with broad relevance for understanding metabolic-epigenetic crosstalk in disease.

• Cabazitaxel (XRP6258): Protocol Guidance for Resistant Model

  2026-07-29

  Cabazitaxel (XRP6258) addresses the challenge of taxane resistance in cancer research by enabling targeted disruption of microtubule dynamics in P-glycoprotein-expressing tumor models. It is not suitable for aqueous-based systems or long-term solution storage and requires strict attention to solvent selection and preparation. For robust results, researchers should adhere to precise workflow and QC protocols.

• Lenalidomide (CC-5013) in Myeloma: Mechanistic Depth & Epige

  2026-07-29

  Explore the multifaceted mechanisms of Lenalidomide (CC-5013) in multiple myeloma research, including recent epigenetic synergy discoveries. This article delivers advanced scientific insight and practical guidance not found in existing protocols.

• CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1

  2026-07-28

  This study reveals that Cdc2-like kinase 2 (CLK2) is upregulated in ovarian cancer and confers resistance to platinum chemotherapy by phosphorylating BRCA1 at Ser1423, enhancing DNA damage repair. Targeting CLK2 represents a promising strategy to overcome platinum resistance and improve treatment outcomes.

• YAP-TEAD Super-Enhancer Regulation in Surface Ectoderm Commi

  2026-07-28

  Wang et al. (2026) demonstrate that the YAP-TEAD transcriptional complex orchestrates super-enhancer networks to drive early surface ectoderm differentiation from pluripotent stem cells. This work advances understanding of epigenetic regulation in lineage commitment and informs protocols for epithelial regeneration.

• Quaternized Nanoassemblies Enable Lung-Targeted mRNA Deliver

  2026-07-27

  This study introduces a quaternization-based modification of lipid-like nanoassemblies, converting their organ targeting from the spleen to the lung for systemic mRNA delivery. The findings offer a simplified strategy for precise pulmonary mRNA translation, expanding the therapeutic and research applications of mRNA technology.

• 3-Hydroxybutyrate (BHBA): Protocols for Neuroprotection Rese

  2026-07-27

  3-hydroxybutyrate (BHBA) is transforming metabolic and epigenetic assay design by enabling precise modeling of neuroprotection, ferroptosis inhibition, and chromatin regulation. This guide delivers actionable workflows, optimization strategies, and troubleshooting tips to maximize the reproducibility and translational value of BHBA-based experiments.

450 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page